May 23 |
We Think Some Shareholders May Hesitate To Increase Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation
|
May 11 |
Coherus BioSciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
May 10 |
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript
|
May 10 |
Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript
|
May 9 |
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
|
May 9 |
Coherus BioSciences Non-GAAP EPS of -$0.32 misses by $0.11, revenue of $77.1M misses by $6.65M
|
May 9 |
Coherus BioSciences Reports First Quarter 2024 Financial ResultsĀ and Provides Business Update
|
May 9 |
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
|
May 8 |
Coherus BioSciences Q1 2024 Earnings Preview
|
May 8 |
When Can We Expect A Profit From Coherus BioSciences, Inc. (NASDAQ:CHRS)?
|